

European Association of Urology Nurses Fellowship Programme

Short-term visit: min. 1 - max. 2 weeks

HOST INSTITUTION APPLICATION FORM

Institutional Name	University College London Hospitals		
Department Address	Urology UCLH at Westmoreland Street, 16-18 Westmoreland Street, London W1G8PH		
Contact Person E-mail	Hilary Baker hilary.baker2@nhs.net		
Website www.uclh.nhs.uk/urologicalcance		<u>ogicalcancers</u>	
Capacity Maximum number of Fell accommodated at one tir Maximum number of fello Suitable time of year	ne ows per year	28spring and autumn	
Languages spoken by a Please indicate the languages the staff in the areas of y based. 1. ✓ English 2. ☐ French 3. ☐ German 4. ☐ Spanish 5. ☐ Other:	ages that are confidentl	ly spoken by a majority of In where Fellows will be	



Facilities

Please indicate the ability of your Hospital / Institution to provide the following facilities for Fellows

Accommodation at reasonable cost close to the Hospital There is some hospital accommodation which is very be on a first come serve basis as it is predominantly for pa	asic and	comes
Dining facilities	√ Yes	□ No
Nursing Mentor for the duration of the Fellow's visit	√ Yes	□ No

Programme

From the lists below please indicate (v) the types of programmes and experience that a visiting Fellow might experience in your Hospital Institution. Please tick as many boxes as you feel appropriate and feel free to list other areas of urology.

/	General Programme		√ S	Spe	pecialised Programme	
	✓ ✓> ☐	Ward Operating Room Outpatients Department Other [Please specify]		□	Paediatric urology Urodynamics Stone Treatment Lithotripsy Continence management Prostate Disease Microwave Therapy Home / Ambulant care Palliative care Other: Tumour site- cific care/treatments	

Other requirements

In the space below, please list any other requirements your Hospital / Institution has in providing the Fellowship programme

- Uro-oncology treatments/care Library
- Opportunities to tailor a week's training to the students requirements
- Macmillan Cancer Centre
- Based in central London easy access to shops and London sights



Enclosures

20/11/117

In completion of this final section, please refer to the appropriate appendix for information.

(App If 'Y	alth Certificate Required. Dendix) Yes', please indicate the type of The es that require addressing in s	f certification re	
	If no active participation in the needed.	ie patient care,	health certificate is not
Ag	reement to act as a Host I	lospital / Ins	titution
I,	KIKA BADAN		_, Head of Department, - Atm
ha	ve read the rules pertaining t		•
ар	plication of		to act as a Host
Ins	stitution.		
	Ofin.	Signature	e of Head of Department Acom Uracy

Date



Description of Hospital / Institution

In no more than 300 words please provide a brief description of your Hospital / Institution indicating issues such as bed numbers, geographical location and population served. Please type this section.

Demographic Profile of UCLH Population Served

UCLH, is situated in the heart of London, is one of the most complex NHS trusts, serving a large and diverse population. In July 2004 UCLH were one of the first NHS trusts in England to achieve foundation trust status. The hospitals provide academically led acute and specialist services, both locally and to patients from throughout the United Kingdom and overseas. UCLH balance the provision of highly rated, specialist services with providing acute services to the local populations of Camden, Islington, Barnet, Enfield, Haringey and Westminster, with over 50% of activity now commissioned by NHS England as part of specialist services contracts. UCLH's turnover is £885 million and are contracted with over 90 commissioning bodies. UCLH see over 950,000 outpatients, over 125,000 A&E attendances and admit over 156,000 patients each year.

UCLH Is Made Up Of Six Hospitals:

- University College Hospital (incorporating the Elizabeth Garrett Anderson Wing);
- Eastman Dental Hospital (EDH);
- National Hospital for Neurology and Neurosurgery (NHNN)
- Heart Hospital (HH);
- Royal London Hospital for Integrated Medicine (RLHIM);
- Royal National Throat Nose and Ear Hospital (RNTNE).

UCLH is one of the country's five, Government funded comprehensive biomedical research centres, and were re-designated by the National Institute for Health Research as one in 2011 – meaning that new research will establish how our patients are treated. UCLH are the founding member of UCL Partners which brings together a number of Britain's world renowned medical research centres and hospitals, including: Bart's Health, Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), Moorefield's Eye Hospital NHS Foundation Trust, Queen Mary University of London, Royal Free NHS Foundation Trust, University College London (UCL) and University College London Hospitals NHS Foundation Trust. UCL Partners was officially designated as one of the UK's first academic health science centres by the Department of Health in March 2009. Alongside the close relationship with the Royal Free and University College Medical School, UCLH have good links with London South Bank and City Universities which offer high quality training and education.

Vanguard Sites

In 2015 NHS England called for applications as part of the NHS 'Five Year Forward' from organisations across the country to **become vanguard**



sites and to provide new programme of care models, with cancer care being described as a clinical priority.

Their aim is to spread excellence in hospital services and management, driving efficiency and improvement across the country. University College London Hospitals (UCLH) NHS Foundation Trust has joined forces with two other leading hospitals; The Royal Marsden and The Christie Hospital with the intention to innovate, expand existing cancer networks, to improve early diagnosis, new diagnostic models and develop more work streams across the entire pathway, to reduce variations in the quality and cost of care.

The Five Year Forward View predicts that the cost of cancer services will grow by 9% a year, which means this, could rise to £13 billion per annum by 2020/21. UCLH cancer programme director Jonathan Gardner says: 'We have an opportunity to influence positive outcomes and experience and to reduce variation.' He also states that "in the future, cancer nurse specialists may be employed by one organisation but work across a number of organisations, and in primary and secondary care. We need to break down barriers between organisations. There may be some initial costs, but in the long term, diagnosing people with cancer in the early stages will save life, which is the most important thing and to save money." Nurses are playing important leadership roles across the vanguards, by being involved in patient journeys and working across systems, including primary and secondary care. This is an opportunity for nurses to make a difference in cancer care.

Reconfiguration of Cardiovascular and Cancer Services

UCLH support the UCL Partners strategy to reconfigure cardiovascular and cancer services across North Central and North East London, concentrating specialist activity in fewer, better equipped centres, seeing more patients with the aim to improve patient outcomes and the overall quality of care. UCH want the whole population to benefit from the national and international excellence in diagnosis, treatment and care that we deliver here at the UCLH. The work on cancer emphasises partnership working, so that patients are seen locally whenever this is possible. The vanguard will try to resolve all this by getting commissioners to take a common approach and, providers to adopt the same clinical and operational standards.

In early 2013, London Cancer proposed to commissioners that UCLH be designated the centre for prostate and bladder surgery. There have been previous commissioner decisions to centralise most of the brain cancer and teenage cancer services at UCLH, as part of a process to increase the volume of specialist activities in fewer centres, drive up experience and, clinically improved outcomes. It has also been suggested that UCLH might be best suited to take a leadership role in the overall organisation of radiotherapy for the North Central and East London Cancer network for the same reason although, much of this service will continue to be provided locally. In October 2013 London Cancer produced a 'Case for Change in Specialist Cancer and Cardiac Services'. This cancer proposal is being considered by commissioners and is based on a plan to centralise still further, specialist episodes of the cancer patients' journey at UCLH across North East and North Central London. The particular areas of focus



are bladder and prostate cancer, Upper GI, Head and Neck and, Brain cancer (along with Queens Hospital

Romford). Haematological cancer are now centralised at UCLH and Bart's Health with important local high level service provision available where appropriate. As part of the discussions around cancer reconfiguration, a parallel set of discussions took place recommending to the commissioners the centralisation of cardiovascular services to Bart's Health across a similar health economy. With all cardiac services moving from the Heart Hospital and the London Chest Hospital, the aim would be to create an integrated cardiovascular system, while thoracic surgery will be retained and moved to the main University College Hospital site, with a plan for growth and expansion, as part of the overall desire to improve the outcomes of patients with lung cancer.

Urology Services

The Division of Surgical Specialities comprises of Trauma and Orthopaedics, Urology, Head and Neck and, Thoracic's. The Division has a large inpatient base for elective surgery, but also includes a significant day case, non-elective and outpatient workload. There are 143 inpatient beds, approximately 13,000 inpatient episodes and 55,000 outpatient episodes per year; it is a busy Division with a wide variety of strategic and operational priorities. The urology department has a body of 20 consultants ably supported by an expert team of nurse specialists and clinical nurse practitioners. The Directorate is divided into male reconstruction, female urology and reconstruction, andrology, oncology and stones and provides services for paediatric (in association with GOSH), adolescents and adults with urological problems for both local services users and tertiary referrals

The majority of urology inpatient services and outpatients clinics are provided at University College Hospital at Westmoreland Street (the former Heart Hospital). Cardiac services have transferred from UCLH to Bart's Heart Centre at St Bartholomew's Hospital, This forms part of an NHS England plan to improve cancer services.

Geoff Bellingan, medical director for UCLH's surgery and cancer board said: "Moving urology services and continuing to have thoracic surgery at Westmoreland Street supports our plan to improve cancer services and will enable us to develop both services.

Cancer Services

UCLH provides a wide range of cancer services including all types of cancer treatment and almost all tumour types. Workload has increase significantly over recent years in all areas, except paediatric inpatients, where there has been a shift away from inpatient treatment. Chemotherapy treatments have increased at 8% per annum over the same period. UCLH have identified cancer as a service where they want to be a European leader. In the short term the priorities include maximising opportunities of the innovative service models in the new Cancer Centre, delivering a step change in patient experience (in partnership with Macmillan Cancer Support) and implementing the Proton Beam Therapy strategic development. The key short term strategic objectives will be:



- Support delivery of the proposed reconfiguration of specialist cancer services in North East and North Central London
- Deliver appropriate business cases to ensure the Proton Beam Therapy and Phase 4 above ground facility are delivered in 2018
- Improve the experience of cancer patients and their families across the health system, in partnership with Macmillan Cancer support
- Improve outcomes through world leading translational research, in partnership with UCL and Cancer Research UK